

REMARKSIntroductory Matters

Claims 1-27 are pending in this application.

Applicants have amended claim 1 to delete "derivative or prodrug" and substitute therefore "salt." Support for this amendment may be found throughout the specification as originally filed (see, e.g., page 28, lines 12-26).

This amendment adds no new matter.

The Office Action35 U.S.C. § 112, first paragraph

Claims 11-27 stand rejected under 35 U.S.C. § 112, first paragraph as lacking enablement. The Examiner contends that the specification "while being enabling for the treatment of colon cancer, does not reasonably provide enablement for the treatment of all other diseases embraced by the instant claims." Applicants would like to discuss a reply to these rejections with the Examiner by telephone.

Claims 1-7 and 9-27 also stand rejected under 35 U.S.C. § 112, first paragraph as lacking enablement. The Examiner contends that although the specification is enabling "for the compound or a pharmaceutically acceptable salt thereof" (emphasis in original), the specification is not enabling for derivatives or prodrugs of the compound. The Examiner has suggested amending the claims to delete "derivative or prodrug" and substitute therefore "salt." Applicants have amended claim 1 as suggested by the Examiner thus obviating these rejections.

35 U.S.C. § 102

Claims 1-5 and 9-27 stand rejected under 35 U.S.C. § 102(a) as being anticipated by Armistead et al., WO 01/60816 (published August 23, 2001) and as being anticipated by Pease et

al., WO 01/64655 (published September 7, 2001). Claims 1-5 and 9-27 also stand rejected under 35 U.S.C. § 102(a) as being anticipated by Bradbury et al., WO 00/39101. Applicants would like to discuss a reply to these rejections with the Examiner by telephone.

35 U.S.C. § 103

Claims 1-5 and 9-27 stand rejected under 35 U.S.C. § 103 as being obvious over Bradbury et al., WO 00/39101. Applicants would like to discuss a reply to these rejections with the Examiner by telephone.

Conclusion

Accordingly, applicants request that the Examiner enter the above amendments and consider the foregoing remarks.

Respectfully submitted,



Lisa A. Dixon
Registration No. 40,995
Attorney for Applicants
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Telephone: (617) 444-6100
Facsimile: (617) 444-6438